Novo Nordisk is trading 4.4% up at $46.50 in pre-market action, rebounding from recent volatility as investors react to the company raising its full-year 2026 outlook.
- The company raised its FY2026 sales and operating profit guidance following a Q2 revenue beat driven by sustained high demand for its GLP-1 treatments.
- While earnings per share were impacted by impairment charges, the underlying growth in core segments has bolstered investor confidence.
- Additional support is coming from a firm healthcare sector, providing a positive backdrop for the stock's post-earnings recovery.